La cadena de opciones muestra datos clave de las opciones de acciones de VYNE Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para VYNE Therapeutics..

VYNE Therapeutics (NASDAQ:VYNE) Bolsa, Cadena de Opciones

VYNE THERAPEUTICS INC

VYNE Therapeutics

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

VYNE Therapeutics Inc

TAT Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) (TASE: TATT) ("TAT" or the "Company"), a leading provider of products and services to the commercial and military aerospace and ground defense industries, announced today that it has commenced an underwritten public offering of ordinary shares. 1,625,000 ordinary shares are being offered by TAT and 2,525,000 ordinary shares are being offered by FIMI Opportunity V, L.P. and FIMI Israel Opportunity Five, Limited Partnership (the "Selling Shareholders"). TAT and the Selling Shareholders intend to grant the underwriters an option to purchase up to an additional 242,298 and 380,202 ordinary shares, respectively, at the public offering price less the underwriting discount and commissions.
TAT intends to use the net proceeds that it will receive from the offering for general corporate purposes, including working capital and capital expenditures.&nbsp;TAT will not receive any proceeds from the sale of ordinary shares being offered by the Selling Shareholders.
The offering is subject to market and other conditions, and there can be no assurance as to whether, or when, the offering may be completed or as to the actual size or terms of the offering.

News

Offerings

TATT

TAT Technologies Launches Underwritten Public Offering Of 4.15M Ordinary Shares, Including 1.625M By Company And 2.525M By FIMI Selling Shareholders

ATS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATS#NYSE">ATS</a>) reported quarterly earnings of $0.41 per share. This is a 36.92 percent decrease over earnings of $0.65 per share from the same period last year. The company reported $721.10 million in sales this quarter. This is a 8.89 percent decrease over sales of $791.50 million the same period last year.

Earnings

ATS Q4 Adj. EPS $0.41 Down From $0.65 YoY, Adj. Sales $721.10M Down From $791.50M YoY

Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) has outperformed the market over the past 20 years by 1.54% on an annualized basis producing an average annual return of 9.8%. Currently, Honeywell Intl has a market capitalization of $144.48 billion. 
Buying $100 In HON: If an investor had bought $100 of HON stock 20 years ago, it would be worth $649.24 today based on a price of $224.60 for HON at the time of writing.
<h3>Honeywell Intl's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748466926_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) raises FY2026 Adj EPS guidance from $11.09-$11.17 to $11.27-$11.33 vs $11.16 analyst estimate. Raises FY2026 sales outlook from $40.50 billion-$40.90 billion to $41.00 billion-$41.30 billion vs $40.83 billion estimate.

Guidance

Salesforce Raises FY2026 Adj EPS Guidance from $11.09-$11.17 to $11.27-$11.33 vs $11.16 Est; Raises FY2026 Sales Guidance from $40.50B-$40.90B to $41.00B-$41.30B vs $40.83B Est

General

NWTN

NWTN Obtains Nasdaq Delisting Determination Letter For Non-Compliance with Listing Rule 5250(c)(1)

Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) is looking for Q2 Adj EPS of $2.76-$2.78 vs $2.73 analyst estimate. sees sales of $10.110 billion-$10.160 billion vs $10.01 billion analyst estimate.

Salesforce Sees Q2 Adj EPS $2.76-$2.78 vs $2.73 Est; Sees Sales $10.110B-$10.160B vs $10.01B Est

ATS (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATS#TSX">ATS</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.28 by 46.43 percent. This is a 36.92 percent decrease over earnings of $0.65 per share from the same period last year. The company reported quarterly sales of $721.10 million which beat the analyst consensus estimate of $689.21 million by 4.63 percent. This is a 8.89 percent decrease over sales of $791.50 million the same period last year.

Earnings Beats

TSX:ATS

ATS Q4 Adj. EPS $0.41 Beats $0.28 Estimate, Sales $721.10M Beat $689.21M Estimate

Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) raises FY2026 Adj EPS guidance from $0.66-$0.69 to $0.69-$0.72 vs $0.70 analyst estimate. Raises FY2026 sales outlook from $574.50 million-$578.50 million to $578.50 million-$582.50 million vs $579.63 million estimate.

NCNO

Ncino Raises FY2026 Adj EPS Guidance from $0.66-$0.69 to $0.69-$0.72 vs $0.70 Est; Raises FY2026 Sales Guidance from $574.50M-$578.50M to $578.50M-$582.50M vs $579.63M Est

SentinelOne Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) reported financial results for the first quarter after the market close on Wednesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/05/b45656397/sentinelone-announces-first-quarter-fiscal-year-2026-financial-results">from the quarter</a>.
Q1 Earnings: SentinelOne reported first-quarter revenue of $229.03 million, beating the&nbsp;<a href="http://benzinga.com/quote/s/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $228.35 million, according to&nbsp;<a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The cybersecurity company reported first-quarter adjusted earnings of two cents per share, in line with analyst estimates.
Total revenue increased 23% year-over-year. Annualized recurring revenue (ARR)&nbsp;increased 24% year-over-year to $948.1 million as of April 30. Customers with ARR of $100,000 or more grew 22% to 1,459 in the quarter. 
The company ended the period with $1.2 billion in cash, cash equivalents and investments. SentinelOne&#8217;s board also authorized a $200 million share repurchase program. 
&#8220;Our top-tier growth and margin improvement reflect continued platform momentum and customer success,&#8221; said&nbsp;Tomer Weingarten, CEO of SentinelOne.
&#8220;Our innovation engine is fueling adoption across AI, Data, Cloud and Endpoint. With Singularity, we&#8217;re leading a transformational shift toward AI-powered security for the future.&#8221;
Guidance:&nbsp;SentinelOne expects second-quarter revenue of approximately $242 million versus estimates of $244.88 million. The company also lowered its full-year 2026 revenue guidance from $1.007 billion to a range of $996 million to $1.001 billion. Analysts were expecting full-year revenue of $1.01 billion.
Shares appear to be selling off in reaction to the soft outlook. SentinelOne executives are currently discussing the quarter on a conference call with investors and analysts that kicked off at 4:30 p.m. ET.
S Price Action: <a href="https://www.benzinga.com/quote/S" target="_blank" rel="noreferrer noopener">SentinelOne shares</a> were down 11.44% in after-hours, trading at $17.42 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong">Nvidia Q1 Highlights: China Export Ban Hits Results But Jensen Huang Says Demand &#8216;Incredibly Strong&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/tadaimages">Tada Images</a>/Shutterstock.

After-Hours Center

Movers

Tech

SentinelOne Q1 Earnings: Revenue Beat, EPS In Line, Shares Dive On Soft Guidance

<h3>Gainers</h3>
<ul>
<li>KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) shares rose 8.4% to $55.75 during Wednesday's after-market session. The company's market cap stands at $3.9 billion. </li>
<li>Outdoor Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) shares rose 7.14% to $1.8. The company's market cap stands at $213.7 million. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) stock increased by 6.48% to $0.33. The market value of their outstanding shares is at $23.3 million. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) shares rose 6.18% to $0.83. The company's market cap stands at $90.0 million. </li>
<li>Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) stock moved upwards by 5.45% to $1.45. The company's market cap stands at $4.6 million. </li>
<li>Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) shares increased by 5.04% to $3.33. The company's market cap stands at $74.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LiveWire Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) shares declined by 13.1% to $3.45 during Wednesday's after-market session. The market value of their outstanding shares is at $702.3 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) stock decreased by 7.33% to $4.53. The company's market cap stands at $49.8 million. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares decreased by 7.32% to $0.4. The market value of their outstanding shares is at $1.5 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) stock fell 7.11% to $2.09. The company's market cap stands at $598.1 million. </li>
<li>Top Win International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SORA#NASDAQ">SORA</a>) shares decreased by 6.85% to $11.71. The company's market cap stands at $291.1 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares fell 6.02% to $1.73. The market value of their outstanding shares is at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTNT

GDHG

JFBR

JZXN

LCUT

LVWR

POWW

PRPL

SORA

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock increased by 39.5% to $0.99 during Wednesday's after-market session. The market value of their outstanding shares is at $48.8 million. </li>
<li>ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) shares rose 17.92% to $7.04. The company's market cap stands at $500.4 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock increased by 16.87% to $1.0. </li>
<li>Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) shares moved upwards by 16.44% to $273.06. The market value of their outstanding shares is at $44.4 billion. As per the press release, Q1 earnings came out today. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares moved upwards by 14.75% to $2.8. The market value of their outstanding shares is at $601.0 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares rose 13.17% to $0.36. The company's market cap stands at $5.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) stock fell 13.6% to $0.8 during Wednesday's after-market session. The company's market cap stands at $76.6 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares decreased by 12.48% to $0.35. The market value of their outstanding shares is at $9.5 million. </li>
<li>Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) shares fell 11.5% to $8.55. The company's market cap stands at $885.6 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares decreased by 9.53% to $0.19. The company's market cap stands at $6.1 million. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) stock decreased by 8.09% to $2.16. The market value of their outstanding shares is at $120.7 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares decreased by 7.88% to $0.24. The market value of their outstanding shares is at $14.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASBP

BIAF

IMUX

INDP

KLTO

NAOV

NTLA

ORIC

SPRO

TSHA

VEEV

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) stock moved upwards by 5.4% to $1.37 during Wednesday's after-market session. The market value of their outstanding shares is at $47.4 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) stock moved upwards by 5.11% to $3.7. The market value of their outstanding shares is at $126.2 million. </li>
<li>Diana Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSX#NYSE">DSX</a>) stock rose 5.07% to $1.45. The company's market cap stands at $167.8 million. </li>
<li>iPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) shares increased by 4.98% to $0.48. The market value of their outstanding shares is at $14.9 million. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock rose 4.95% to $0.36. The market value of their outstanding shares is at $4.5 million. </li>
<li>Robin Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) stock increased by 4.71% to $2.85. The company's market cap stands at $6.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) stock declined by 14.8% to $0.22 during Wednesday's after-market session. The company's market cap stands at $51.0 million. </li>
<li>Elong Power Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) shares fell 14.29% to $3.0. The market value of their outstanding shares is at $150.1 million. </li>
<li>New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) shares declined by 6.46% to $0.92. The market value of their outstanding shares is at $28.7 million. </li>
<li>FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) shares fell 5.64% to $3.85. The market value of their outstanding shares is at $50.3 million. </li>
<li>Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) stock decreased by 5.41% to $1.75. The market value of their outstanding shares is at $89.8 million. </li>
<li>Rain Enhancement (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIN#NASDAQ">RAIN</a>) stock declined by 4.83% to $4.34. The company's market cap stands at $32.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVGI

ELPW

FTCI

HOVR

LNZA

NEOV

RAIN

RBNE

UGRO

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>HeartCore Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) stock increased by 25.1% to $0.73 during Wednesday's after-market session. The company's market cap stands at $16.0 million. </li>
<li>C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) stock increased by 14.68% to $26.4. The company's market cap stands at $3.4 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares increased by 10.56% to $6.8. The company's market cap stands at $1.3 billion. </li>
<li>Lightwave Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) shares increased by 6.93% to $1.08. The company's market cap stands at $135.0 million. </li>
<li>BitFuFu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) shares rose 6.3% to $3.71. The company's market cap stands at $604.3 million. </li>
<li>Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) stock increased by 6.25% to $19.19. The company's market cap stands at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) stock decreased by 14.0% to $23.4 during Wednesday's after-market session. The market value of their outstanding shares is at $22.0 billion. As per the news, the Q2 earnings report came out today. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) shares fell 12.79% to $1.91. The market value of their outstanding shares is at $6.9 million. </li>
<li>MicroCloud Hologram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) stock decreased by 11.54% to $9.2. The company's market cap stands at $47.1 million. </li>
<li>SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) shares declined by 11.35% to $17.44. The company's market cap stands at $5.7 billion. As per the press release, Q1 earnings came out today. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) shares decreased by 4.77% to $0.8. The company's market cap stands at $15.5 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) shares decreased by 3.92% to $0.98. The company's market cap stands at $25.3 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BASE

FUFU

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HTCR

LWLG

NVTS

SMSI

12 Information Technology Stocks Moving In Wednesday's After-Market Session

RILY

B. Riley Financial Receives Delinquency Notification Letter From Nasdaq

WESTFORD, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Kadant Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAI#NYSE">KAI</a>) announced it received orders with a combined value of $18 million from three lumber producers in North America and Europe since its first quarter earnings call. The capital equipment orders are expected to ship between the end of 2025 and the third quarter of 2026. The equipment and technologies to be supplied will be used to debark, strand, chip, and batch feed whole logs and lumber wastewood to produce oriented strand board (OSB) and dimensional lumber. Smart technology systems developed by Kadant will further optimize the wood processing operations by leveraging key data in the production process.

Contracts

Kadant Secures $18M In Capital Equipment Orders From Three North American And European Lumber Producers For Delivery by Q3 2026

Across the recent three months, 6 analysts have shared their insights on Tripadvisor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Tripadvisor, revealing an average target of $14.83, a high estimate of $18.00, and a low estimate of $11.00. Highlighting a 6.14% decrease, the current average has fallen from the previous average price target of $15.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1748466073_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Tripadvisor's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$11.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Tripadvisor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Tripadvisor compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Tripadvisor's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Tripadvisor's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TRIP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Tripadvisor analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Tripadvisor: A Closer Look</h2>
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
<h3>Tripadvisor: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Tripadvisor showcased positive performance, achieving a revenue growth rate of 0.76% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Communication Services sector.
Net Margin: Tripadvisor's net margin is impressive, surpassing industry averages. With a net margin of -2.76%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Tripadvisor's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -1.39%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.41%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.97, Tripadvisor faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

TRIP

Analyst Expectations For Tripadvisor's Future

XCUR

Exicure Receives Nasdaq DelinquencyLetter Regarding Late Filing Of Its Form 10-Q

Across the recent three months, 4 analysts have shared their insights on New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $51.25, a high estimate of $53.00, and a low estimate of $50.00. This current average has decreased by 3.3% from the previous average price target of $53.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1748466050_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of New Jersey Resources by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Sunderland</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Gabriel Moreen</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Sarah Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$53.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$51.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to New Jersey Resources. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of New Jersey Resources compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of New Jersey Resources's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into New Jersey Resources's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NJR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on New Jersey Resources analyst ratings.</a>
<h2>Discovering New Jersey Resources: A Closer Look</h2>
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include investments in commercial solar projects and several large midstream natural gas projects.
<h3>New Jersey Resources: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: New Jersey Resources displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 38.78%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Utilities sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 22.37%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): New Jersey Resources's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): New Jersey Resources's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.83% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 1.38, New Jersey Resources faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where New Jersey Resources Stands With Analysts

In the last three months, 4 analysts have published ratings on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Teva Pharmaceutical Indus and provided 12-month price targets. The average target is $22.5, accompanied by a high estimate of $25.00 and a low estimate of $20.00. Witnessing a positive shift, the current average has risen by 5.49% from the previous average price target of $21.33.
<img src="https://www.benzinga.com/files/images/story/2025/1748466040_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Teva Pharmaceutical Indus by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teva Pharmaceutical Indus. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Teva Pharmaceutical Indus's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TEVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teva Pharmaceutical Indus analyst ratings.</a>
<h2>Unveiling the Story Behind Teva Pharmaceutical Indus</h2>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
<h3>Understanding the Numbers: Teva Pharmaceutical Indus's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Teva Pharmaceutical Indus's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.89% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Teva Pharmaceutical Indus's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 5.5%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Teva Pharmaceutical Indus's ROE excels beyond industry benchmarks, reaching 3.68%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Teva Pharmaceutical Indus's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.55%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.71, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TEVA

Where Teva Pharmaceutical Indus Stands With Analysts

In the latest quarter, 11 analysts provided ratings for CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CubeSmart, revealing an average target of $46.36, a high estimate of $50.00, and a low estimate of $39.00. Highlighting a 0.17% decrease, the current average has fallen from the previous average price target of $46.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1748466031_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of CubeSmart among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ravi Vaidya</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$48.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Jeffrey Spector</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Daniel Tricarico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Ravi Vaidya</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$39.00</td>
<td>-</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$49.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Todd Thomas</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Tricarico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$46.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CubeSmart. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CubeSmart compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CubeSmart's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CUBE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CubeSmart analyst ratings.</a>
<h2>Get to Know CubeSmart Better</h2>
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Majority of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. The company derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
<h3>CubeSmart's Economic Impact: An Analysis</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: CubeSmart's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 4.45%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: CubeSmart's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 32.67%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.12%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): CubeSmart's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.36% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: CubeSmart's debt-to-equity ratio is below the industry average. With a ratio of 1.21, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CUBE

Analyst Expectations For CubeSmart's Future

Health Care

Press Releases

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

VYNE Therapeutics to Participate in March Investor Conferences

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

VYNE Therapeutics Provides Update on VYN202 Program

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

Comments

VYNE Therapeutics

VYNE Therapeutics (VYNE) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL